Annovis Bio Receives NYSE Noncompliance Listing Notice
The company failed to meet minimum market capitalization and stockholders' equity standards required for continued listing.
Updated on Oct. 30, 2026 in Public Companies
Live Poll
Do you prioritize investing in companies that maintain consistent regulatory listing standards?
The New York Stock Exchange has issued a noncompliance notice to Annovis Bio after the company failed to meet minimum continued-listing standards for market capitalization and stockholders' equity. This regulatory alert signals a potential risk to the company's standing on the exchange.
Why it matters
Listing notices serve as a critical alert to investors and stakeholders that a company has fallen below the exchange's solvency and valuation thresholds, necessitating a plan to regain compliance. These developments often signal internal financial strain and can trigger increased volatility for shareholders.
Annovis Bio reported a 30-day average market capitalization of $48.4 million and a stockholders' deficit of $4.3 million. These figures triggered a noncompliance notice from the New York Stock Exchange.
The players
Annovis Bio
A biotechnology company focused on developing therapies for neurodegenerative diseases.
New York Stock Exchange
The world's largest stock exchange by market capitalization that enforces listing and compliance standards for public companies.
The details
The NYSE enforces strict baseline requirements for public companies to maintain their listed status, specifically regarding valuation and capital structure. Annovis Bio failed to maintain the required minimums for its market value and equity, which are calculated based on rolling trading averages and periodic balance sheet reports. The notice compels the firm to address these deficits to avoid potential delisting from the exchange.
Timeline
June 30, 2026: Annovis Bio reported a stockholders' deficit of approximately $4.3 million.
October 28, 2026: The company calculated a 30-day average market capitalization of approximately $48.4 million.
October 29, 2026: The New York Stock Exchange issued a noncompliance notice to the firm.
Market Landscape
This notice follows the standard enforcement protocols established under NYSE Listed Company Manual Section 802.01 regarding minimum market capitalization and stockholders' equity. It represents a formal step in the exchange's process for managing companies that fail to meet these core financial performance benchmarks.
Operators should monitor whether the company submits a compliant plan to the exchange to avoid delisting, which would impact liquidity and secondary financing. Financial teams should verify that their own capitalization and equity reporting aligns with the requirements of the specific exchange on which they trade.
The takeaway
Maintaining listing compliance requires consistent oversight of both market-based valuation and balance-sheet equity. Operators should track company filings for remediation updates and any correspondence with exchange regulators regarding listing standing.
Further reading
For more on how regulatory enforcement affects capital access, visit Public Companies.
Source note: This article includes information reported by TokenPost.
Live Poll
Do you prioritize investing in companies that maintain consistent regulatory listing standards?
